期刊文献+

标准剂量和半量缓释型达必佳在体外受精-胚胎移植中治疗效果的比较 被引量:20

Comparative Study of Full Dose and Half Dose of Decapeptyl in IVF
下载PDF
导出
摘要 目的 :探索一种在体外受精 -胚胎移植 ( IVF-ET)超排卵方案中既能使垂体降调节又不至于过度抑制卵巢功能的达必佳有效剂量。方法 :比较 2 4位接受 IVF-ET助孕者的治疗效果 ,一组 1 4例( A组 )皮下注射半支 ( 1 .88mg)达必佳缓释型 ;一组 1 0例 ( B组 )接受缓释型达必佳标准剂量 3 .75mg/支。结果 :B组在使用促性腺激素 ( Gn)前及绒毛膜促性腺激素 ( h CG)注射日的黄体生成素( LH)水平明显低于 A组 ( 1 .1 6± 0 .45 IU/L vs 2 .3 8± 0 .79IU/L,P<0 .0 1 ;0 .84± 0 .60 IU/L vs2 .1 4± 0 .71 IU/L,P<0 .0 1 )。 Gn用量及用药时间大于 A组 ( 4 0 .9± 1 2 .7支 vs 3 0 .9± 4.2支 ,P<0 .0 5 ;1 4.2± 3 .0 d vs 1 1 .4± 1 .6d,P<0 .0 1 ) ,二组的 h CG注射日雌二醇 ( E2 )水平、获卵数、受精率、卵裂率、妊娠率均无统计学差异 ( P>0 .0 5 )。二组均无内源性 LH峰出现。结论 :半量达必佳能获得与全量达必佳相同的治疗结果、且能减少 Objective:To investigate the optimal dose of Decapeptyl that used in the IVF superovulation protocol for the pituitary desensitization. Methods:Twenty four patients with tube infertility were involved in the study and divided into two groups according to the dose of Decapeptyl inject ed in midluteal phase; group A included 14 patients had a single dose of 1.88 mg Decapeptyl, group B had 10 patients injected a single dose of 3.75 mg Dec apeptyl. Results:The LH levels were 2.38±0.79 IU/L in g roup A and 1.16± 0.45 IU/L in group B before the day of gonadotropin, and we re 2.14±0.17 IU/L in group A and 0.84±0.60 IU/L in group B on the day of hCG. The LH level of group B was significantly lower than group A (P<0.01). The mean amount of gonadotropin was higher in group B (40.9±12.7 ampules) than in group A (30.9±4.2 ampules)(P<0.05). The length of simulation was significan tly increased in group B (14.2±3.0 days) compared with group A (11.4±1.6 days) (P<0.01). There was no difference between two groups in E 2 levels on the d ay of hCG, the number of oocytes retrieved, fertilization rate, cleavage rate an d pregnancy rate. No premature endogenous LH surge occurred in either group. Conclusion:Half dose of Decapeptyl used in IVF treatme nt achieved same effectiveness as full dose of Decapeptyl, resulting in reduct ion of the dose of gonadotropin, the length of stimulation and the cost of tre atment.
出处 《生殖与避孕》 CAS CSCD 北大核心 2002年第4期243-246,共4页 Reproduction and Contraception
  • 相关文献

参考文献11

  • 1Bstandig B, Cedrin-Durnerin I & Hugues JN. Effec tiveness of low dose of gonadotropin releasing hormone agonist on hormonal flare up. J Assisted Reprod Genetics, 2000,17 : 1 13 ~ 117.
  • 2Raphael RonelL, Eliahu Caspi, Abraham Golan, et al. A comparison of clomiphene/menotropins and D-Trp6-LH-RH/menotropins cycles of IVF-ET in the same patiens. Iht J Fertil, 1991,36:157~161.
  • 3Balasch J, Gomez F, Carmona R, et al. Pituitary -ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Human Reprod, 1992,7:1 230~1 234.
  • 4Simon A,Benshushan A, Shusan A, et al. A compari son between a standard and reduced dose of D-Trp-6luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization. Human Reprod, 1994, 9; 1 813~1 817.
  • 5Peter R & Brinsden R. The Bourn Hall Quide to Clini cal and Laboratory Practice, In vitro Fertilization and Assisted Reproduction. New York: The Parthenon Publishing Group Ltd, 1999 ,p. 91~ 102
  • 6ZHUANG Guang-lun & ZHOU Can-quan. In vitro fertilization and transfer embryo. In: LUO Li-lan. ed. Infertility and Infecundity (in Chinese). Beijing: People's Medical Publication House, 1998, p. 415.
  • 7Happ J, Schuhheiss H, Jacobi GH,et al. Phaemacodynamics, Pharmacokinetics and bioavailability of prolonged LH-RH agonist-SR. In JGM Klijin. ed. Hormonal Manipulation of Cancermograph Series of the European Organization for Research on Treatment for Cacer, Vol 18, New York: Raven Press, 1987, p. 249
  • 8Dor J, Bider D, Shulman A, et al. Effects of go nadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro-results of a prospective, randomizd in-vitro fertilization study. Human Reprod, 2000, 15:1 225~1 230.
  • 9Miro F, Sampaio MC, Tarin JJ, et al. Steroidogenesis in vitro of human granulosa-luteal cells pretreated in vivo with two gonadotropin releasing hormone analogs employing different protocols. Gynecol Endocrinol, 1992,6 : 77~84.
  • 10Smitz JEI, Ron R & Tarlatzis BC. The use of go nadotrophin releasing hormone agonists for in-vitro fertilization and other assisted procreation techniques: experience from three centers. Hum Reprod, 1992, 7 (Suppl. 1): 49~46.

同被引文献162

引证文献20

二级引证文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部